Endoscopic Retrograde Cholangiopancreatography
1 other identifier
observational
100
1 country
1
Brief Summary
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2026
CompletedFirst Submitted
Initial submission to the registry
March 18, 2026
CompletedFirst Posted
Study publicly available on registry
March 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
March 24, 2026
February 1, 2026
1 year
March 18, 2026
March 18, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Underwent ERCP
Patients undergoing ERCPs at Methodist Dallas Medical Center.
25 years
Study Arms (1)
Underwent ERCP
Underwent ERCP between January 1, 2000 through December 31, 2025
Interventions
The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.
Eligibility Criteria
Patients who underwent ERCP and in MDI(Methodist Digestive Institute) registry.
You may qualify if:
- Patients \>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025
You may not qualify if:
- Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Methodist Dallas Medical Center- Clinical Research Institute
Dallas, Texas, 75203, United States
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Prashant Kedia, MD
Methodist Health System
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Target Duration
- 25 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 18, 2026
First Posted
March 24, 2026
Study Start
February 1, 2026
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
February 1, 2028
Last Updated
March 24, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
The investigator will make all possible efforts to ensure compliance with all policies regarding sharing of Protected Health Information or research information. Only de-identified Protected Health Information will be shared in relevant research mediums.